- Home
- QUIK vs EQ Comparison
QUIK vs EQ Comparison
Compare QUIK & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QUIK
- EQ
- Stock Information
- Founded
- QUIK 1988
- EQ 2017
- Country
- QUIK United States
- EQ United States
- Employees
- QUIK N/A
- EQ N/A
- Industry
- QUIK Semiconductors
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- QUIK Technology
- EQ Health Care
- Exchange
- QUIK Nasdaq
- EQ Nasdaq
- Market Cap
- QUIK 100.1M
- EQ 85.1M
- IPO Year
- QUIK 1997
- EQ 2018
- Fundamental
- Price
- QUIK $6.51
- EQ $1.54
- Analyst Decision
- QUIK Strong Buy
- EQ Hold
- Analyst Count
- QUIK 3
- EQ 2
- Target Price
- QUIK $10.87
- EQ $1.00
- AVG Volume (30 Days)
- QUIK 168.6K
- EQ 792.1K
- Earning Date
- QUIK 11-10-2025
- EQ 11-12-2025
- Dividend Yield
- QUIK N/A
- EQ N/A
- EPS Growth
- QUIK N/A
- EQ N/A
- EPS
- QUIK N/A
- EQ N/A
- Revenue
- QUIK $18,359,000.00
- EQ $16,553,000.00
- Revenue This Year
- QUIK N/A
- EQ N/A
- Revenue Next Year
- QUIK $77.05
- EQ N/A
- P/E Ratio
- QUIK N/A
- EQ N/A
- Revenue Growth
- QUIK N/A
- EQ N/A
- 52 Week Low
- QUIK $4.26
- EQ $0.27
- 52 Week High
- QUIK $13.36
- EQ $2.35
- Technical
- Relative Strength Index (RSI)
- QUIK 61.28
- EQ 52.65
- Support Level
- QUIK $5.86
- EQ $1.31
- Resistance Level
- QUIK $6.37
- EQ $1.54
- Average True Range (ATR)
- QUIK 0.39
- EQ 0.12
- MACD
- QUIK 0.05
- EQ -0.02
- Stochastic Oscillator
- QUIK 71.37
- EQ 68.50
About QUIK QuickLogic Corporation
QuickLogic Corp provides programmable silicon and software platforms to enable its customers to develop custom hardware products in a fast time-to-market and cost-effective way. QuickLogic is a fabless semiconductor company with a product range: embedded FPGA (eFPGA) intellectual property (IP), low power, multi-core semiconductor system-on-chips (SoCs), discrete FPGAs, and AI software. The full range of platforms, software tools, and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across Aerospace, and Defense, Consumer/Industrial IoT, and Consumer Electronics markets.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.